Literature DB >> 28328094

Asthma management: A new phenotype-based approach using presence of eosinophilia and allergy.

M Terl1, V Sedlák1, P Cap2, R Dvořáková1, V Kašák1, T Kočí2, B Novotna2, E Seberova2, P Panzner2, V Zindr1.   

Abstract

Asthma is a heterogeneous disease. The Czech Pneumology and Allergology Societies commissioned 10 experts to review the literature and create joint national guidelines for managing asthma, reflecting this heterogeneity. The aim was to develop an easy-to-use diagnostic strategy as a rational approach to the widening opportunities for the use of phenotype-targeted therapy. The guidelines were presented on websites for public comments by members of both the societies. The reviewers' comments contributed to creating the final version of the guidelines. The key hallmark of the diagnostic approach is the pragmatic concept, which assesses the presence of allergy and eosinophilia in each asthmatic patient. The guidelines define three clinically relevant asthma phenotypes: eosinophilic allergic asthma, eosinophilic nonallergic asthma and noneosinophilic nonallergic asthma. The resulting multifunctional classification describing the severity, level of control and phenotype is the starting point for a comprehensive treatment strategy. The level of control is constantly confronted with the intensity of the common stepwise pharmacotherapy, and the concurrently included phenotyping is essential for phenotype-specific therapy. The concept of the asthma approach with assessing the presence of eosinophilia and allergy provides a way for more precise diagnosis, which is a prerequisite for using widening options of personalized therapy.
© 2017 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

Entities:  

Keywords:  allergy; asthma heterogeneity; eosinophilia; phenotype-specific therapy

Mesh:

Year:  2017        PMID: 28328094     DOI: 10.1111/all.13165

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  10 in total

Review 1.  Evolution of our view on the IgE molecule role in bronchial asthma and the clinical effect of its modulation by omalizumab: Where do we stand today?

Authors:  Jakub Novosad; Irena Krčmová
Journal:  Int J Immunopathol Pharmacol       Date:  2020 Jan-Dec       Impact factor: 3.219

2.  Real-world effectiveness and safety of omalizumab in patients with uncontrolled severe allergic asthma from the Czech Republic.

Authors:  Olga Růžičková Kirchnerová; Tomáš Valena; Jakub Novosad; Milan Teřl
Journal:  Postepy Dermatol Alergol       Date:  2018-06-20       Impact factor: 1.837

3.  Type A behavior pattern, risk propensity and empathy in young professionally active patients with bronchial asthma.

Authors:  Andrzej Witusik; Piotr Kuna; Tadeusz Pietras; Lukasz Mokros
Journal:  Postepy Dermatol Alergol       Date:  2018-11-08       Impact factor: 1.837

Review 4.  Immunological methods for diagnosis and monitoring of IgE-mediated allergy caused by industrial sensitizing agents (IMExAllergy).

Authors:  Xaver Baur; Cezmi A Akdis; Lygia Therese Budnik; Maria Jesus Cruz; Axel Fischer; Ulrike Förster-Ruhrmann; Thomas Göen; Ozlem Goksel; Astrid R Heutelbeck; Meinir Jones; Harald Lux; Piero Maestrelli; Xavier Munoz; Benoit Nemery; Vivi Schlünssen; Torben Sigsgaard; Claudia Traidl-Hoffmann; Paul Siegel
Journal:  Allergy       Date:  2019-06-27       Impact factor: 13.146

5.  Effect of individual allergen sensitization on omalizumab treatment outcomes in patients with severe allergic asthma determined using data from the Czech Anti-IgE Registry.

Authors:  Petr Vaník; Jakub Novosad; Olga Kirchnerová; Irena Krčmová; Milan Teřl
Journal:  Allergy Asthma Clin Immunol       Date:  2020-09-15       Impact factor: 3.406

Review 6.  PM2.5 Exposure and Asthma Development: The Key Role of Oxidative Stress.

Authors:  Kaimeng Liu; Shucheng Hua; Lei Song
Journal:  Oxid Med Cell Longev       Date:  2022-04-04       Impact factor: 6.543

Review 7.  Eosinophilic Asthma, Phenotypes-Endotypes and Current Biomarkers of Choice.

Authors:  Konstantinos Porpodis; Ioanna Tsiouprou; Apostolos Apostolopoulos; Polyxeni Ntontsi; Evangelia Fouka; Despoina Papakosta; Harissios Vliagoftis; Kalliopi Domvri
Journal:  J Pers Med       Date:  2022-06-30

8.  Serum periostin levels in asthma patients in relation to omalizumab therapy and presence of chronic rhinosinusitis with nasal polyps.

Authors:  Jakub Novosad; Irena Krčmová; Vladimír Bartoš; Marcela Drahošová; Petr Vaník; Olga Růžičková-Kirchnerová; Milan Teřl; Jan Krejsek
Journal:  Postepy Dermatol Alergol       Date:  2020-05-06       Impact factor: 1.837

Review 9.  Future research trends in understanding the mechanisms underlying allergic diseases for improved patient care.

Authors:  Heimo Breiteneder; Zuzana Diamant; Thomas Eiwegger; Wytske J Fokkens; Claudia Traidl-Hoffmann; Kari Nadeau; Robyn E O'Hehir; Liam O'Mahony; Oliver Pfaar; Maria J Torres; De Yun Wang; Luo Zhang; Cezmi A Akdis
Journal:  Allergy       Date:  2019-06-04       Impact factor: 13.146

Review 10.  The Intriguing Role of Interleukin 13 in the Pathophysiology of Asthma.

Authors:  Giancarlo Marone; Francescopaolo Granata; Valentina Pucino; Antonio Pecoraro; Enrico Heffler; Stefania Loffredo; Guy W Scadding; Gilda Varricchi
Journal:  Front Pharmacol       Date:  2019-12-06       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.